• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024

    3/25/24 6:38:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NBY alert in real time by email

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

    Date/Time:

     

    Tuesday, March 26, 4:30 p.m. ET / 1:30 p.m. PT

     

     

     

    Pre-Registration:

     

    Participants can pre-register for the conference call here:

     

     

     

     

     

    Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.

     

     

     

    Dial In:

     

    Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:

     

    833-816-1121 from within the U.S.

     

    412-317-1862 from outside the U.S.

    The live webcast of the conference call also will be available on the Events section of the Company website. A replay of the call will be available beginning two hours after its completion through April 16, 2024 by dialing 877-344-7529 from within the U.S., 855-669-9658 from Canada or 412-317-0088 from outside the U.S., and entering conference ID 1489846. The webcast will also be archived here.

    About NovaBay Pharmaceuticals, Inc:

    NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare and wound care products. NovaBay's leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to consumers through online distribution channels such as Amazon.com. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by China Pioneer Pharma Holdings, Limited. More information about NovaBay is available here.

    Socialize and Stay Informed on NovaBay's Progress

    Like us on Facebook

    Follow us on X

    Connect with NovaBay on LinkedIn

    Visit NovaBay's Website

    Avenova Purchasing Information

    For NovaBay Avenova purchasing information:

    Please call 800-890-0329 or email [email protected]

    Avenova.com

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240325019136/en/

    Get the next $NBY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NBY

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Lazar David E. claimed no ownership of stock in the company (SEC Form 3)

    3 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    8/26/25 4:18:44 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:50:08 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:46:27 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    SEC Filings

    View All

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    8/26/25 4:06:38 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    8/19/25 5:29:08 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by NovaBay Pharmaceuticals Inc.

    10-Q - NovaBay Pharmaceuticals, Inc. (0001389545) (Filer)

    8/14/25 4:36:08 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

    EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed NovaBay's Chief Executive Officer and a director of the Company. Former Chief Executive Officer Justin Hall has assumed the newly created position of Vice President of Business Development. At NovaBay's Special Meeting on April 16, 2025, stockholders

    8/19/25 5:25:32 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders

    Stockholders as of the March 18, 2025 record date will be entitled to vote Company engages financial advisor to explore strategic options should stockholders fail to approve the dissolution proposal NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it will hold a virtual Special Meeting on April 16, 2025, at which stockholders will vote on a proposal for the liquidation and dissolution of the Company under Delaware law, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Dissolution"). The Special Meeting was announced in a preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission ("SEC") on F

    3/7/25 6:50:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Poplar Point Capital Partners Lp bought $15,967 worth of shares (28,731 units at $0.56) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:50:08 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $74,519 worth of shares (123,365 units at $0.60) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:46:27 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Poplar Point Capital Partners Lp bought $30,718 worth of shares (49,927 units at $0.62) (SEC Form 4)

    4 - NovaBay Pharmaceuticals, Inc. (0001389545) (Issuer)

    4/15/25 12:40:59 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Leadership Updates

    Live Leadership Updates

    View All

    Innovations in Disinfection Technology Aid the Return of Workers

    NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

    12/9/20 9:00:00 AM ET
    $NBY
    $CEMI
    $BSGM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $NBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    11/8/24 5:31:40 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/14/24 2:52:33 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

    SC 13G/A - NovaBay Pharmaceuticals, Inc. (0001389545) (Subject)

    2/13/24 5:17:39 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NBY
    Financials

    Live finance-specific insights

    View All

    NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share

    EMERYVILLE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces its Board of Directors and the Special Transaction Committee of the Board of Directors has declared a one-time special cash dividend of $0.80 per share of common stock. The special cash dividend will be payable on September 29, 2025 to stockholders of record as of the close of business on September 15, 2025. "This special dividend reflects our commitment to creating and returning value directly to our stockholders," said David Lazar, CEO of NovaBay. "I'm excited about the Company's future as we explore several interesting strategic alternatives." Because

    8/26/25 4:05:00 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

    EMERYVILLE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces it has entered into a $6 million securities purchase agreement with private investor David E. Lazar for the purchase of the Company's non-voting convertible preferred stock. NovaBay has received $3.85 million in the first of two closings under the agreement. Effective immediately, Mr. Lazar has been appointed NovaBay's Chief Executive Officer and a director of the Company. Former Chief Executive Officer Justin Hall has assumed the newly created position of Vice President of Business Development. At NovaBay's Special Meeting on April 16, 2025, stockholders

    8/19/25 5:25:32 PM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

    NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT   Pre-Registration: Participants can pre-register for the conference call here:   Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and

    8/1/24 6:50:00 AM ET
    $NBY
    Biotechnology: Pharmaceutical Preparations
    Health Care